Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer

Rad, Ellie and Tee, Andrew ORCID: https://orcid.org/0000-0002-5577-4631 2016. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Seminars in Cell & Developmental Biology 52 , pp. 39-46. 10.1016/j.semcdb.2016.02.007

[thumbnail of 0484.pdf]
Preview
PDF - Submitted Pre-Print Version
Download (1MB) | Preview

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant tumour predisposition syndrome that is caused through loss of function mutations of a tumour suppressor gene called Neurofibromin 1. Therapeutic options are currently limited for NF1-associated tumours, where treatment is often restricted to complete surgical resection with clear margins. Herein, we discuss the multifunctional tumour suppressive role of neurofibromin, which is classically known as a GTPase activating protein (GAP) towards the RAS small GTPase. While neurofibromin inhibits proliferative growth through blockade of RAS-mediated signal transduction, neurofibromin should also be considered as a modulator of cell motility and cell adhesion. Through interfacing with the cytoskeleton and membrane structures, neurofibromin acts as a negative regulator of RHO/ROCK signalling pathways involved in cytoskeletal dynamics that are instrumental in proper neuronal development. In the context of cancer, the loss of normal function of neurofibromin via genetic mutation results in heightened cell proliferation and migration, predisposing NF1 patients to cancer. Malignant Peripheral Nerve Sheath Tumours (MPNSTs) can develop from benign neurofibromas and are the main cause of death amongst NF1 patients. Through recent research on MPNSTs, we have gained insight into the key molecular events that drive their malignancy. Advances regarding malignant drivers involved in cell migration, cell invasion and angiogenic signalling are discussed in this review, where these findings will likely influence future therapies for both NF1 and related sporadic cancers.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Uncontrolled Keywords: NF1, MPNST, Neurofibromin, Cancer, Tumour suppressor
Publisher: Elsevier
ISSN: 1084-9521
Date of Acceptance: 3 February 2016
Last Modified: 06 Nov 2023 23:20
URI: https://orca.cardiff.ac.uk/id/eprint/103710

Citation Data

Cited 55 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics